GALATI, GIOVANNI
 Distribuzione geografica
Continente #
AS - Asia 3.337
NA - Nord America 325
EU - Europa 193
OC - Oceania 6
SA - Sud America 6
AF - Africa 3
Totale 3.870
Nazione #
SG - Singapore 3.102
US - Stati Uniti d'America 316
CN - Cina 112
HK - Hong Kong 102
GB - Regno Unito 49
IT - Italia 45
DE - Germania 32
FI - Finlandia 17
CZ - Repubblica Ceca 15
NL - Olanda 14
FR - Francia 8
TR - Turchia 8
CA - Canada 7
IN - India 7
PL - Polonia 6
AU - Australia 5
SE - Svezia 3
BR - Brasile 2
CL - Cile 2
ES - Italia 2
MX - Messico 2
PE - Perù 2
UA - Ucraina 2
ZA - Sudafrica 2
AE - Emirati Arabi Uniti 1
AZ - Azerbaigian 1
CY - Cipro 1
JP - Giappone 1
KI - Kiribati 1
KZ - Kazakistan 1
MA - Marocco 1
SA - Arabia Saudita 1
Totale 3.870
Città #
Singapore 114
Hong Kong 100
Ashburn 77
Boardman 55
Hefei 52
London 44
Shanghai 36
Munich 22
Rome 20
Brno 15
Seattle 15
San Francisco 12
Council Bluffs 11
Los Angeles 10
West Jordan 10
Amsterdam 9
Turku 9
Helsinki 8
Santa Clara 8
Washington 7
Pune 6
Sona 5
Toronto 5
Warsaw 5
Guangzhou 4
New York 4
Paris 3
Secaucus 3
Stockholm 3
Boydton 2
Brooklyn 2
Camden 2
Canberra 2
Central 2
Lima 2
Melbourne 2
Naples 2
São Paulo 2
Zhengzhou 2
Almere Stad 1
Ankara 1
Augusta 1
Boston 1
Buffalo 1
Changchun 1
Chicago 1
Cleveland 1
Cold Lake 1
Dallas 1
Foligno 1
Frankfurt am Main 1
Fuzhou 1
Gauteng 1
Genoa 1
Handan 1
Hangzhou 1
Hanover 1
Jinan 1
Johannesburg 1
Las Vegas 1
Mexico City 1
Milan 1
Nanyang 1
Newark 1
Nicosia 1
Pingxiang 1
Rabat 1
Riyadh 1
Rockville 1
Salt Lake City 1
Shenzhen 1
Slough 1
Stow 1
Suffern 1
Sydney 1
Tarawa 1
The Dalles 1
Tianjin 1
Tokyo 1
Trieste 1
Wuxi 1
Xingtai 1
Totale 735
Nome #
Angiogenic cytokines in patients undergoing antiviral treatment for chronic hepatitis C virus infection 193
A case of Henoch-Schönlein purpura in the elderly: not just a 'second childhood' 193
A mocking finding: portal cavernoma mimicking neoplastic mass. First sign of myeloproliferative disorder in a patient with Janus kinase2 V617F mutation 190
Breath-print analysis by e-nose may refine risk stratification for adverse outcomes in cirrhotic patients 188
Anti-tumor necrosis factor-alpha reverts growth hormone resistance associated with inflammatory bowel disease 187
Deep vein thrombosis, inferior vena cava interruption and multiple thrombophilic gene mutations 185
Hepatic expression of lysosomal acid lipase is reduced in non-alcoholic fatty liver disease and inversely associated with the degree of microvescicular steatosis, impairment of the autophagic process and NAFLD activity score 183
METAL HOMEOSTASIS IN PATIENTS WITH PORTO-SYSTEMIC ENCEPHALOPATHY 180
Breath-print analysis by e-nose for classifying and monitoring chronic liver disease: a proof-of-concept study 179
Distortion-product otoacoustic emissions: a useful test for monitoring ototoxicity induced by pegylated interferon and ribavirin treatment in patients with chronic hepatitis C 178
The hepatic expression of lysosomal acid lipase (LAL) is reduced in NAFLD patients, and associated with features of genetically determined LAL deficiency and NAFLD activity score 172
BREATH PRINT ANALYSIS BY E-NOSE IS ASSOCIATED WITH ADVERSE OUTCOMES OF CIRRHOTIC PATIENTS INDEPENDENTLY FROM THE OTHER PROGNOSTIC INDICES 170
Assessment of liver function by the exhaled breath-print during chronic liver disease 166
Development and Validation of a Scoring System to Predict Response to Obeticholic Acid in Primary Biliary Cholangitis 164
THU-390 - Hepatic expression of lysosomal acid lipase is reduced in non-alcoholic fatty liver disease and inversely associated with the degree of microvescicular steatosis, impairment of the autophagic process and NAFLD activity score 121
Diabetes in chronic liver disease: from old concepts to new evidence 92
Coexistence of HBsAg and HBsAb in a difficult-to-treat chronic hepatitis B: loss of HBsAg with entecavir plus tenofovir combination 90
Diagnostic value of Virtual Touch Quantification (VTQ®) for differentiation of hemangiomas from malignant focal liver lesions 82
A challenging alfa-fetoprotein in a cirrhotic patient 80
Acoustic Radiation Forced Impulse of the Liver and the Spleen, Combined with Spleen Dimension and Platelet Count in New Ratio Scores, Identifies High-Risk Esophageal Varices in Well-Compensated Cirrhotic Patients 79
METAL METABOLISM IMPAIRMENT IN PATIENTS WITH HEPATIC ENCEPHALOPATHY 79
Cardiotrophin-1 is not associated with carotid or coronary disease and is inversely associated with obesity in patients undergoing coronary angiography 79
Determinants of alanine aminotransferase levels in a large population from Southern Italy: relationship between alanine aminotransferase and age 75
Current Treatment Options for HCC: From Pharmacokinetics to Efficacy and Adverse Events in Liver Cirrhosis 67
Combining genetic variants to improve risk prediction for nafld and its progression to cirrhosis: a proof of concept study 50
Lysosomal acid lipase activity is reduced both in cryptogenic cirrhosis and in cirrhosis of known etiology 28
Real-world experience with obeticholic acid in patients with primary biliary cholangitis 27
Predictors of serious adverse events and non-response in cirrhotic patients with primary biliary cholangitis treated with obeticholic acid 25
Hepatocellular carcinoma in alcoholic liver disease: current management and recent advances 25
Hepatic toll-like receptor 4 expression is associated with portal inflammation and fibrosis in patients with NAFLD 22
Subcellular shift of the hepatic growth hormone receptor with progression of hepatitis C virus-related chronic liver disease 22
Infliximab reverses growth hormone resistance associated with inflammatory bowel disease 22
Lower schooling, higher hepatitis C virus prevalence in Italy: an association dependent on age 20
Hepatic complications of bariatric surgery : the reverse side of the coin 20
Telaprevir raises the plasma/whole blood ribavirin ratio: trying to come full circle on a dangerous relationship 20
Surgical complications after resection of adrenal carcinoma 19
Hepatitis C treatment in the elderly: New possibilities and controversies towards interferon-free regimens 18
GAS EXCHANGE AND PULMONARY MICROCIRCULATION ABNORMALITIES IN CIRRHOTIC AND NON-CIRRHOTIC CHRONIC LIVER DISEASE PATIENTS FREE FROM HEPATOPULMONARY SYNDROME 18
Hepatitis C virus and metabolic disorder interactions towards liver damage and atherosclerosis 18
Hepatitis C and double-hit B cell lymphoma successfully treated by antiviral therapy 17
Haemorrhoidal disease in severe portal hypertension: a combined approach with transjugular intrahepatic portosystemic shunt (TIPS) and transanal haemorrhoidal dearterialization (THD) 16
Peripheral graft infection due to Staphylococcus aureus without abnormal findings by 99mTc-HMPAO-labeled-leukocyte scan 16
Non-cirrhotic portal hypertension with large regenerative nodules: a diagnostic challenge 15
HCV NS3 sequencing as a reliable and clinically useful tool for the assessment of genotype and resistance mutations for clinical samples with different HCV-RNA levels 15
Lack of reduction of serum alphafetoprotein during treatment with direct antiviral agents predicts hepatocellular carcinoma development in a large cohort of patients with HCV-related cirrhosis 14
Non‐invasive assessment of hepatic steatosis by ultrasound‐derived fat fraction in individuals at high‐risk for metabolic dysfunction‐associated steatotic liver disease 13
Platelet count may impact on lysosomal acid lipase activity determination in dried blood spot 13
Platelet Count Does Not Predict Bleeding in Cirrhotic Patients: Results from the PRO-LIVER Study 11
The PNPLA3 rs738409 C > G polymorphism is associated with the risk of progression to cirrhosis in NAFLD patients 11
Lack of reduction in serum alpha-fetoprotein during treatment with direct antiviral agents predicts hepatocellular carcinoma development in a large cohort of patients with hepatitis C virus-related cirrhosis 11
Portal vein thrombosis relevance on liver cirrhosis: Italian Venous Thrombotic Events Registry 9
Totale 3.887
Categoria #
all - tutte 21.346
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 21.346


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/202283 0 0 4 0 0 2 0 0 5 0 0 72
2022/202333 6 0 1 1 0 2 9 4 0 1 9 0
2023/2024194 8 13 6 20 13 79 2 13 3 12 7 18
2024/20253.571 35 17 55 9 55 66 51 7 111 183 1.481 1.501
2025/20266 6 0 0 0 0 0 0 0 0 0 0 0
Totale 3.887